Please link to the full article below or read my summary
[DOI] [PubMed] [Google Scholar] Chopra A, Saluja M, Tillu G
Given so many people are taking these drugs, Yeo said, he expects longer-term trial data to emerge in the coming years that will provide a more certain picture
The primary pharmacodynamic distinctions between long-acting and short-acting GLP-1RAs are that long-acting agonists augment insulin production and suppress glucagon generation to lower postprandial glucose and fasting plasma glucose, while short-acting agonists chiefly lower postprandial glucose by delaying gastric emptying
In September 2023, the FDA placed both on its Category 2 list of bulk substances that raise significant safety risks (FDA, 2023)
Tailored Appetite Suppressants Cravings